Parkinson’s UK and Critical Path Institute Launch the Critical Path for Parkinson’s (CPP) Consortium October 14, 2015 Parkinson’s UK and Critical Path Institute Launch the Critical Path for Parkinson’s (CPP) Consortium Data fro
Considerations for Requiring Subjects to Provide a Response to Electronic Patient-Reported Outcome Instruments
January 10, 2015 A Collaborative Approach for “ReSeq-Ing” Mycobacterium Tuberculosis Drug Resistance: Convergence for Drug and Diagnostic Developers
January 10, 2015 Global Collaboration to Develop New and Existing Drugs for Neonates Davis JM, Turner MA. Global Collaboration to Develop New and Existing Drugs for Neonates. JAMA pediatrics. 2015 Oct;169(10):887–
Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson’s Disease Stephenson D, Hu MT, Romero K, Breen K, Burn D, Ben-Shlomo Y, Bhattaram A, Isaac M, Venuto C, Kubota K, Little MA, Friend S, Loves
Evidentiary Considerations for Integration of Biomarkers in Drug Development Symposium Evidentiary Considerations for Integration of Biomarkers in Drug Development Symposium On August 21st, the University of Maryland&
Collaboration is Making LIFE Better: Critical Path Institute Celebrates Key Milestones AZ Bionindustry Association